Denali Therapeutics (DNLI) Income towards Parent Company (2017 - 2026)

Denali Therapeutics (DNLI) has reported Income towards Parent Company for 10 consecutive years, with -$129.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Income towards Parent Company rose 5.05% year-over-year to -$129.0 million; the TTM figure through Mar 2026 stood at -$562.5 million (down 20.88% YoY), while the FY2025 annual figure was -$512.5 million, down 21.23% from the prior year.
• Income towards Parent Company climbed to -$129.0 million in Q1 2026 per DNLI's latest filing, from -$131.4 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $183.4 million in Q2 2023 and bottomed at -$172.2 million in Q2 2025.
• Historically, Income towards Parent Company has averaged -$94.7 million across 5 years, with a median of -$110.1 million in 2024.
• Annual changes were most pronounced in 2023 — Income towards Parent Company jumped 411.91% — and 2024, when it sank 155.56%.
• Denali Therapeutics' Income towards Parent Company stood at -$98.7 million in 2022, then dropped by 21.07% to -$119.5 million in 2023, then climbed by 1.59% to -$117.6 million in 2024, then fell by 11.79% to -$131.4 million in 2025, then grew by 1.84% to -$129.0 million in 2026.
• Business Quant data shows DNLI's Income towards Parent Company at -$129.0 million in Q1 2026, -$131.4 million in Q4 2025, and -$129.9 million in Q3 2025.